Importantly, clinical datasets further supported the correlations between GFPT1/ANGPTL4 expression and cholesterol levels in Non-Alcoholic Steatohepatitis (NASH) liver cancer patients. The gene discussed is GFPT1; the disease is metabolic dysfunction-associated steatohepatitis.